Cal-1 Drug Product
HIV-1 Infection
Assistance Publique - Hôpitaux de Parisgene_therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
62 Active assets in the HIV-1 Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltegravir Helsinki University Central Hospital | Phase 4 | A |
ZIDOVUDINE International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Phase 4 | BBB |
Efavirenz The Cleveland Clinic | Phase 4 | BBB |
Ganciclovir | Phase 4 | BBB |
RITONAVIR Giovanni Di Perri | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →